New York state approval is a pivotal moment for Renalytix. Approval facilitates the launch of KidneyIntelX with launch partner Mount Sinai and progressively derisks the investment hypothesis. Understandably with Mount Sinai in the heart of the NYC Covid-19 health pandemic, testing and first commercial revenues is now set to begin in calendar Q3 2020 (vs Q2 2020) once the integration of KidneyIntelX into the Mount Sinai electronic health record is completed. Renalytix is now licensed to provide K ....
12 Jun 2020
NY State approval – KidneyIntelX to launch in Q3 – derisking valuation
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
NY State approval – KidneyIntelX to launch in Q3 – derisking valuation
Renalytix Plc (RENX:LON) | 30.0 0 0.0% | Mkt Cap: 37.9m
- Published:
12 Jun 2020 -
Author:
Edward Thomason -
Pages:
3
New York state approval is a pivotal moment for Renalytix. Approval facilitates the launch of KidneyIntelX with launch partner Mount Sinai and progressively derisks the investment hypothesis. Understandably with Mount Sinai in the heart of the NYC Covid-19 health pandemic, testing and first commercial revenues is now set to begin in calendar Q3 2020 (vs Q2 2020) once the integration of KidneyIntelX into the Mount Sinai electronic health record is completed. Renalytix is now licensed to provide K ....